Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Analyst Ratings
Moderate Buy
15 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRTX Stock 12 Month Forecast
Average Price Target
$488.86
▲(19.88% Upside)
| Highest Price Target$624.00 | Average Price Target$488.86 | Lowest Price Target$401.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citi
$575
Buy
41.00%
Upside
Reiterated
10/10/25
Morgan Stanley
$439→$438
Hold
7.41%
Upside
Reiterated
10/10/25
Evercore ISI
$475
Buy
16.48%
Upside
Reiterated
10/09/25
Cantor Fitzgerald
$485
Buy
18.93%
Upside
Reiterated
10/09/25
J.P. Morgan
$517→$530
Buy
29.97%
Upside
Reiterated
10/08/25
RBC Capital
$405→$423
Hold
3.73%
Upside
Reiterated
10/08/25
Leerink Partners
$456
Buy
11.82%
Upside
Reiterated
10/07/25
BMO Capital
$530
Buy
29.97%
Upside
Reiterated
10/03/25
Bank of America Securities
$565
Buy
38.55%
Upside
Reiterated
10/03/25
William Blair
―
Buy
―
Reiterated
09/25/25
Vertex Pharmaceuticals' Strategic Acquisition and FDA Breakthrough Designation Boosts Buy RatingWe note that Filspari (full approval), Fabhalta, Vanrafia are already approved for IgAN, indicating the FDA views data from the Phase II RUBY-3 clinical trial, which was used as the basis for granting BTD, as meaningfully differentiated from available therapies. We believe there is a case to be made that the FDA sees B-cell modulators as a class to fulfill an unmet need in IgAN despite Filspari full approval, given BTD is also held by Vera’s (VERA $27.44) atacicept and Otsuka’s (OTSKY $26.66) sibeprenlimab. For IgAN, once monthly subcutaneous 80 mg pove is currently under investigation in the Phase III RAINIER study, which has a prespecified interim analysis (IA) evaluating the urine- protein-to-creatinine ratio (UPCR) after a specified number of participants reach 36 weeks of treatment.
Raymond James
$401
Hold
-1.67%
Downside
Initiated
09/02/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Goldman Sachs
$624
Buy
53.02%
Upside
Reiterated
08/11/25
Canaccord Genuity
$424→$411
Hold
0.79%
Upside
Reiterated
08/06/25
Guggenheim
$558→$546
Buy
33.89%
Upside
Reiterated
08/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citi
$575
Buy
41.00%
Upside
Reiterated
10/10/25
Morgan Stanley
$439→$438
Hold
7.41%
Upside
Reiterated
10/10/25
Evercore ISI
$475
Buy
16.48%
Upside
Reiterated
10/09/25
Cantor Fitzgerald
$485
Buy
18.93%
Upside
Reiterated
10/09/25
J.P. Morgan
$517→$530
Buy
29.97%
Upside
Reiterated
10/08/25
RBC Capital
$405→$423
Hold
3.73%
Upside
Reiterated
10/08/25
Leerink Partners
$456
Buy
11.82%
Upside
Reiterated
10/07/25
BMO Capital
$530
Buy
29.97%
Upside
Reiterated
10/03/25
Bank of America Securities
$565
Buy
38.55%
Upside
Reiterated
10/03/25
William Blair
―
Buy
―
Reiterated
09/25/25
Vertex Pharmaceuticals' Strategic Acquisition and FDA Breakthrough Designation Boosts Buy RatingWe note that Filspari (full approval), Fabhalta, Vanrafia are already approved for IgAN, indicating the FDA views data from the Phase II RUBY-3 clinical trial, which was used as the basis for granting BTD, as meaningfully differentiated from available therapies. We believe there is a case to be made that the FDA sees B-cell modulators as a class to fulfill an unmet need in IgAN despite Filspari full approval, given BTD is also held by Vera’s (VERA $27.44) atacicept and Otsuka’s (OTSKY $26.66) sibeprenlimab. For IgAN, once monthly subcutaneous 80 mg pove is currently under investigation in the Phase III RAINIER study, which has a prespecified interim analysis (IA) evaluating the urine- protein-to-creatinine ratio (UPCR) after a specified number of participants reach 36 weeks of treatment.
Raymond James
$401
Hold
-1.67%
Downside
Initiated
09/02/25
Bernstein
―
Hold
―
Reiterated
08/22/25
Goldman Sachs
$624
Buy
53.02%
Upside
Reiterated
08/11/25
Canaccord Genuity
$424→$411
Hold
0.79%
Upside
Reiterated
08/06/25
Guggenheim
$558→$546
Buy
33.89%
Upside
Reiterated
08/06/25
Best Analysts Covering Vertex Pharmaceuticals
1 Month
xxx
Success Rate
25/32 ratings generated profit
Average Return
+4.44%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 78.13% of your transactions generating a profit, with an average return of +4.44% per trade.
3 Months
xxx
Success Rate
19/27 ratings generated profit
Average Return
+7.00%
upgraded a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +7.00% per trade.
1 Year
Success Rate
24/32 ratings generated profit
Average Return
+20.48%
reiterated a buy rating 5 days ago
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +20.48% per trade.
2 Years
xxx
Success Rate
27/31 ratings generated profit
Average Return
+25.48%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +25.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRTX Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
0
0
2
2
2
Buy
35
36
34
31
33
Hold
39
40
32
25
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
74
76
68
58
53
Each month's total comprises the sum of three months' worth of ratings.
VRTX Financial Forecast
VRTX Stock Forecast FAQ
What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 488.86.
What is VRTX’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 19.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRTX a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 15 buy ratings, 10 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s price target?
The average price target for Vertex Pharmaceuticals is 488.86. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $624.00 ,the lowest forecast is $401.00. The average price target represents 19.88% Increase from the current price of $407.79.
The highest analyst price target is $624.00 ,the lowest forecast is $401.00. The average price target represents 19.88% Increase from the current price of $407.79.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.
How can I buy shares of VRTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.